Company research / Focus view

Natco Pharma

NATCOPHARM · Pharma & Healthcare · small cap · Smallcap 50

Revenue · FY26

₹4,045 cr

-8.3% YoY

What the business sold

Net profit · FY26

₹1,419 cr

-24.8% YoY

What it kept after tax

Operating profit · FY26

₹1,256 cr

-36.6% YoY

Profit from operations

Operating cash flow · FY26

₹1,768 cr

+4.2% YoY

Cash the operations produced

Total debt · FY26

₹714 cr

+155.5% YoY

Borrowings against the business

Dividend per share · FY26

—

Paid out per share · not collected yet

Five years in perspective

Price index · Start = 100 · Dividends excluded · ₹815.35 today (-0.40%)

-16.8% · 5Y

2021 · 10020222023202420252026 · 98.6

1M -10.1%6M -19.8%1Y -3.9%3Y +0.3%5Y -16.8%

Market cap

₹14,870 Cr

As of 13 Sept 2026

Price to earnings

12.8

Price to book 1.6

Dividend yield

73.00%

Trailing twelve months

52-week range

₹789 – ₹1,227

Closing prices

The financial record

₹ crore · Consolidated where reported · Indian fiscal years (April–March)

Reported metric	FY23	FY24	FY25	FY26
Revenue	2,697	3,979	4,412	4,045
Operating profit	790	1,577	1,981	1,256
Net profit	715	1,388	1,885	1,419
Operating cash flow	849	1,212	1,697	1,768
Free cash flow	644	853	1,185	1,377
Capital expenditure	-206	-359	-512	-391
Tax expense	147	285	408	119
Total debt	176	371	279	714
Cash and equivalents	132	70	120	199
Shareholders equity	4,874	5,853	7,607	9,221
Earnings per share (₹)	39.18	77.34	105.26	79.20

Not collected yet for this company: Dividend per share. These come from the filings, not the daily price feed.

Recent quarters

₹ crore · Most recent first

Quarter ended	Revenue	Operating profit	Net profit	EPS (₹)
30 Jun 2026	735	139	207	11.53
31 Mar 2026	739	77	268	14.96
31 Dec 2025	647	113	152	8.46
30 Sept 2025	1,363	527	518	28.94
30 Jun 2025	1,329	513	481	26.84

Developments

0 positive · 0 negative

NeutralCash flow3 days ago

Natco Pharma to Raise Up to Rs 1,300 Cr Through Rights Issue, Revise Demerger Scheme

Natco Pharmasmall cap

Medical Dialogues11 Sept 2026, 8:02 pm IST

Classification & context · Moves the numbers

No supported direction in the headline — that is not the same as unimportant. This classifies the headline only, not the full article. It is not a recommendation.

Names an event that should show up in revenue, profit, debt, capacity or approvals.

Classifier confidence: 0.35. This is not the probability that the report is true.

Neutral3 days ago

Natco Pharma Share Price - Live NSE: NATCOPHARM Stock Price & Chart

Natco Pharmasmall cap

Upstox11 Sept 2026, 12:30 pm IST

Classification & context · Routine

No supported direction in the headline — that is not the same as unimportant. This classifies the headline only, not the full article. It is not a recommendation.

A real announcement — a product, a partnership, an appearance — that is unlikely to change the financials.

Classifier confidence: 0.35. This is not the probability that the report is true.

NeutralCash flow3 days ago

Natco Pharma Rights Issue 2026 Date, Price, Allotment, Ratio

Natco Pharmasmall cap

IPO Watch10 Sept 2026, 11:30 pm IST

Classification & context · Moves the numbers

No supported direction in the headline — that is not the same as unimportant. This classifies the headline only, not the full article. It is not a recommendation.

Names an event that should show up in revenue, profit, debt, capacity or approvals.

Classifier confidence: 0.35. This is not the probability that the report is true.

NeutralCash flow4 days ago

MNC Pharma Giant Announces ₹1,300 Cr Rights Issue; Check Key Details

Natco Pharmasmall cap

IPO Central10 Sept 2026, 5:44 pm IST

Classification & context · Moves the numbers

No supported direction in the headline — that is not the same as unimportant. This classifies the headline only, not the full article. It is not a recommendation.

Names an event that should show up in revenue, profit, debt, capacity or approvals.

Classifier confidence: 0.35. This is not the probability that the report is true.

NeutralCash flow4 days ago

Natco board approves ₹1300-cr fundraiser via rights issue

Natco Pharmasmall cap

pharma.economictimes.indiatimes.com10 Sept 2026, 2:34 pm IST

Classification & context · Moves the numbers

No supported direction in the headline — that is not the same as unimportant. This classifies the headline only, not the full article. It is not a recommendation.

Names an event that should show up in revenue, profit, debt, capacity or approvals.

Classifier confidence: 0.35. This is not the probability that the report is true.

Neutral4 days ago

Eris, Torrent Pharma, Natco, Lupin stand out in Rs157 billion India GLP-1 opportunity: Kotak

Natco Pharmasmall cap GAIL (India)Mentioned Kotak Mahindra BankMentioned LupinMentioned Torrent PharmaceuticalsMentioned

Moneycontrol.com10 Sept 2026, 11:07 am IST

Classification & context · Routine

No supported direction in the headline — that is not the same as unimportant. This classifies the headline only, not the full article. It is not a recommendation.

A real announcement — a product, a partnership, an appearance — that is unlikely to change the financials.

Classifier confidence: 0.35. This is not the probability that the report is true.

Neutral4 days ago

Eris, Torrent Pharma, Natco, Lupin stand out in Rs157 billion India GLP-1 opportunity: Kotak

Alkem Laboratoriesmid cap GAIL (India)Mentioned Kotak Mahindra BankMentioned LupinMentioned Natco PharmaMentioned Torrent PharmaceuticalsMentioned

Moneycontrol.com10 Sept 2026, 11:07 am IST

Classification & context · Routine

No supported direction in the headline — that is not the same as unimportant. This classifies the headline only, not the full article. It is not a recommendation.

A real announcement — a product, a partnership, an appearance — that is unlikely to change the financials.

Classifier confidence: 0.35. This is not the probability that the report is true.

NeutralCash flow5 days ago

Natco Pharma Board Approves Fundraising Up To ₹1,300 Crore Via Rights Issue

Natco Pharmasmall cap

Sahi9 Sept 2026, 6:41 pm IST

Classification & context · Moves the numbers

No supported direction in the headline — that is not the same as unimportant. This classifies the headline only, not the full article. It is not a recommendation.

Names an event that should show up in revenue, profit, debt, capacity or approvals.

Classifier confidence: 0.35. This is not the probability that the report is true.

NeutralCash flow5 days ago

Natco Pharma Board Approves ₹1,300 Crore Rights Issue and Modifies Crop Health Demerger Scheme

Natco Pharmasmall cap

EquityBulls9 Sept 2026, 3:39 pm IST

Classification & context · Moves the numbers

No supported direction in the headline — that is not the same as unimportant. This classifies the headline only, not the full article. It is not a recommendation.

Names an event that should show up in revenue, profit, debt, capacity or approvals.

Classifier confidence: 0.35. This is not the probability that the report is true.

NeutralCash flow5 days ago

NATCO Pharma clears $140M rights issue to fund overseas deals

Natco Pharmasmall cap

Dealroom9 Sept 2026, 1:09 pm IST

Classification & context · Moves the numbers

No supported direction in the headline — that is not the same as unimportant. This classifies the headline only, not the full article. It is not a recommendation.

Names an event that should show up in revenue, profit, debt, capacity or approvals.

Classifier confidence: 0.35. This is not the probability that the report is true.

NeutralCash flow5 days ago

Natco Pharma board approves ₹1,300 crore rights issue

Natco Pharmasmall cap

scanx.trade9 Sept 2026, 12:39 pm IST

Classification & context · Moves the numbers

No supported direction in the headline — that is not the same as unimportant. This classifies the headline only, not the full article. It is not a recommendation.

Names an event that should show up in revenue, profit, debt, capacity or approvals.

Classifier confidence: 0.35. This is not the probability that the report is true.

NeutralCash flow5 days ago

Natco Pharma: Approves ₹1,300 Crore Rights Issue

Natco Pharmasmall cap

InvestyWise9 Sept 2026, 12:39 pm IST

Classification & context · Moves the numbers

No supported direction in the headline — that is not the same as unimportant. This classifies the headline only, not the full article. It is not a recommendation.

Names an event that should show up in revenue, profit, debt, capacity or approvals.

Classifier confidence: 0.35. This is not the probability that the report is true.

NeutralCash flow5 days ago

Natco Pharma Approves Rights Issue Of Equity Shares Up To 13 Billion Rupees

Natco Pharmasmall cap

TradingView9 Sept 2026, 12:06 pm IST

Classification & context · Moves the numbers

No supported direction in the headline — that is not the same as unimportant. This classifies the headline only, not the full article. It is not a recommendation.

Names an event that should show up in revenue, profit, debt, capacity or approvals.

Classifier confidence: 0.35. This is not the probability that the report is true.

NeutralCash flow5 days ago

Natco Pharma NATCOPHARM Rights Issue and Demerger Update

Natco Pharmasmall cap

Kalkine India9 Sept 2026, 11:53 am IST

Classification & context · Moves the numbers

No supported direction in the headline — that is not the same as unimportant. This classifies the headline only, not the full article. It is not a recommendation.

Names an event that should show up in revenue, profit, debt, capacity or approvals.

Classifier confidence: 0.35. This is not the probability that the report is true.

About the business

NATCO Pharma Limited, a pharmaceutical company, engages in the research and development, manufacturing, and marketing of finished dosage formulations, active pharmaceutical ingredients (APIs), and intermediates in India, the United States, and internationally. The company offers formulations in various therapeutic areas, including cancers of blood, liver, kidney, lung, brain, breast, and ovary; and APIs in various categories, such as oncology, central nervous system, pain management, and cardiovascular care. It also provides orthopedic products comprising bisphosphonates, which are oral and injectable drugs; and gastroenterology products consisting of novel drugs for chronic hepatitis-B and hepatitis-C, as well as contract manufacturing services. In addition, the company offers neurology, cardiology and diabetology products for the treatment of hypertension, stable angina, and CHF. Further, the company provides agro chemicals and biological pest management solutions for management of insects, diseases, and weeds across a range of crops. NATCO Pharma Limited was incorporated in 1981 and is headquartered in Hyderabad, India.

Industry: Drug Manufacturers - Specialty & Generic

www.natcopharma.co.in

Data confidence

Prices, fundamentals and developments last verified 13 Sept 2026. Fundamentals are sourced from public filings feeds; interpretation is shown separately from figures.

See the Pharma & Healthcare sector →

Sign in to see the full financial record and classified developments

Guests see a sample. Members get every company, five-year fundamentals, classified developments, a watchlist and the decision journal.